
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is expected to continue seeing strong growth and profitability due to its diverse portfolio of products targeting a broad range of therapeutic areas. The company's strong financials, including a revenue CAGR of 14% and a projected $130 billion in revenue by 2033E, support a positive outlook for its stock. Additionally, Eli Lilly's strategic focus on expanding its global manufacturing and its ability to develop and produce transformative medicines, such as Foundayo, make it well-positioned for future success and multiple expansion.
Bears say
Eli Lilly is facing challenges in its pricing strategies for its key products, with potential pressure from rebates and declining ASPs for Zepbound and Trulicity. There is also uncertainty around the success of tirzepatide and forglipron launch, as well as potential underperformance of pipeline products. While the company may see modest beats in TRx and projected revenue for Q2, there are downside risks and headwinds that could affect the company's financials and stock performance.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares